Khartis Therapeutics
Develops oral small molecule therapies for immunological and chronic diseases
$50MSeries B
Role not disclosedFC
Foresite Capital
Activity from announced rounds
Activity in this selectionSeries B
Foresite Capital is a healthcare investment firm identified by Abcuro and in its own Thyme Care portfolio record.
Recorded funding activity
Abcuro develops immunotherapies targeting pathogenic cytotoxic T cells. Thyme Care combines oncology care teams with technology, while Khartis develops oral medicines for immune and chronic diseases. The company histories distinguish care delivery from experimental drug development.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $50M 1 disclosed · full round size, not this investor’s share